During testing of the developed constructs in <i>in vitro</i> models the constructs exhibited targeted binding to tumor cells expressing the HER2/neu antigen and the agents had a significant stimulating effect on the cytotoxic activity of NK cells against the respective cancer cells. Here, ERBB2 is linked to cancer.